Amgen Sues FDA Over Exclusivity For Blockbuster Sensipar
The U.S. Food and Drug Administration improperly denied extra exclusivity for Amgen Inc.'s blockbuster calcium-control drug Sensipar despite years of exhaustive research conducted at the agency's request, according to a new...To view the full article, register now.
Already a subscriber? Click here to view full article